Table 1.
Baseline characteristics of patients included in PROTHROMCOVID trial.
| N = 300 | Prophylaxis (4500 UI Tinzaparin) Group A (N = 106) |
Intermediate (100 UI/kg Tinzaparin) Group B (N = 91) |
Therapeutic (175 UI/kg Tinzaparin) Group C (N = 103) |
|---|---|---|---|
| Age, Mean (SD) (years) Weight, Median (Q1–Q3) (Kg) BMI Median (Q1–Q3) |
54.1 (15.0) 79.6 (73.0–87.0) 28.5 (25.6–31.1) |
56.5 (14.1) 78.5 (70.0–88.0) 28.6 (25.8–31.2) |
58.5 (14.4) 78.9 (70.0–88.0) 28.7 (25.1–31.9) |
| Men, N (%) Women, N (%) |
63 (59.4%) 43 (40.5%) |
57 (62.6%) 34 (37.3%) |
62 (60.2%) 41 (39.8%) |
| Comorbidities | |||
| Hypertension, N (%) | 29(27.4%) | 34(37.4%) | 36(34.9%) |
| Diabetes mellitus, N (%) | 13 (12.3%) | 17 (18.7%) | 20 (19.4%) |
| Dyslipidemia, N (%) | 26 (24.5%) | 30 (33.0%) | 36 (34.9%) |
| Smoking, N (%) | 5 (4.7%) | 6 (6.6%) | 5 (4.8%) |
| Coronary heart disease, N (%) | 4 (3.8%) | 3 (3.3%) | 3 (2.9%) |
| Chronic obstructive pulmonary disease, N (%) | 3 (2.8%) | 4 (4.4%) | 5 (4.8%) |
| Chronic renal dysfunction, N (%) | 1 (0.9%) | 2 (2.2%) | 3 (2.9%) |
| Prior stroke, N (%) | 3 (2.8%) | 1 (1.1%) | ---% |
| Prior thromboembolic events, N (%) | 1 (0.9%) | 1 (1.1%) | 2 (1.9%) |
| Respiratory severity | |||
| Sat02/ Fi02, Median (Q1–Q3) | 353 (217–452) | 346 (199–450) | 342 (215–477) |
| Laboratory test | |||
| Peak D-dimer, Median (Q1–Q3) (µg/dL) | 618 (375–1100) | 686 (404–1340) | 620 (363–1200) |
| Platelets, Median (Q1–Q3) (×103) | 344 (269–436) | 369 (299–439) | 320 (246–401) |
| IL6 (Q1–Q3), Median (Q1–Q3) (mg/dL) | 23.8 (7.8–50.1) | 29.4 (5.7–63.8) | 21.43 (7.4–43.9) |
| Creatinine, Median (Q1–Q3) (mg/dL) | 0.76 (0.6–0.9) | 0.73 (0.6–0.8) | 0.71 (0.6–0.9) |
| Ferritin, Median (Q1–Q3) (ng/dL) | 619 (274–1275) | 775 (386–1347) | 554 (271–1177) |
| CRP, Median (Q1–Q3) (mg/dL) | 57.6 (25–107) | 60.9 (14–142) | 57.1 (27–131) |
| LDH, Median (Q1–Q3) (ng/dL) | 336 (254–439) | 333 (250–478) | 301 (243–383) |
| ISTH-DIC score, Mean (SD) | 2.42 (0.9) | 2.56 (0.91) | 2.33 (0.76) |
| COVID-19 Treatment | |||
| Steroids, N (%) | 94 (88.6%) | 83 (91.2%) | 91 (88.3%) |
| Remdesivir, N (%) | 20 (18.8%) | 16 (17.5%) | 18 (17.4%) |
| Tocilizumab, N (%) | 16 (15.1%) | 18 (17.4%) | 11 (10.6%) |
| Vaccination Status | |||
| 1 dose | 8 (7.5%) | 12 (13.1%) | 12 (11.6%) |
| 2 doses | 12 (11.3%) | 18 (19.7%) | 16 (15.5%) |
IL6 = Interleukin 6; CRP = C-reactive protein; ISTH-DIC score = International Society of Thrombosis and Haemostasis overt disseminated intravascular coagulation score.